Myalgic Encephalomyelitis/Chronic Fatigue Syndrome After SARS-CoV-2 Infection.
Unger, Elizabeth R, Lin, Jin-Mann S, Wisk, Lauren E et al. · JAMA network open · 2024 · DOI
Quick Summary
This study followed over 4,300 people for up to 12 months to see whether COVID-19 infection caused ME/CFS-like symptoms. Researchers found that about 3-4% of people reported ME/CFS-like symptoms after their acute illness, but this rate was similar whether they had tested positive or negative for COVID-19. The results suggest that while some people do develop long-lasting symptoms after illness, COVID-19 may not be uniquely causing ME/CFS more often than other infections.
Why It Matters
Understanding whether SARS-CoV-2 specifically triggers ME/CFS is critical for affected patients seeking answers about disease causation and for public health planning regarding post-viral complications. This study provides important evidence that ME/CFS-like illness occurs at similar rates regardless of COVID-19 status, informing realistic expectations about long COVID and supporting research into broader post-viral mechanisms.
Observed Findings
ME/CFS-like illness prevalence was 2.8%-3.7% in COVID-19-positive group and 3.1%-4.5% in COVID-19-negative group over 12 months of follow-up.
No significant change in prevalence was observed across the 3-12 month follow-up period in either group.
Adjusted analysis showed no statistically significant difference in odds of ME/CFS-like illness between COVID-19-positive and negative participants (OR range 0.84-1.18).
Survey completion rates declined over time, ranging from 76.3% at 3 months to 38.7% at later timepoints.
Participant population was predominantly female (68.1%) with mean age 37.8 years.
Inferred Conclusions
SARS-CoV-2 infection does not significantly increase the proportion of individuals developing ME/CFS-like illness compared to those with other acute infections.
ME/CFS-like illness occurs at a low but measurable baseline rate (~3-4%) following various acute infections, not exclusively following COVID-19.
The substantial prevalence of ME/CFS-like symptoms even in the non-infected group suggests post-viral ME/CFS may reflect broader post-infectious mechanisms rather than COVID-19-specific pathology.
Remaining Questions
Why did survey completion rates decline substantially over time, and how did this attrition bias the results—particularly whether symptomatic participants were more likely to drop out?
What This Study Does Not Prove
This study does not establish that COVID-19 cannot cause ME/CFS in individual cases, only that the population prevalence is not significantly elevated compared to non-infected controls. The reliance on self-reported symptoms without objective diagnostic markers or biomarifiers means true ME/CFS cases may have been misclassified. Declining follow-up rates over time may bias results if participants with worsening symptoms were more or less likely to remain engaged.
Tags
Symptom:Cognitive DysfunctionFatigue
Phenotype:Infection-TriggeredLong COVID Overlap
Method Flag:PEM Not DefinedWeak Case DefinitionMixed Cohort
Could more sensitive or objective diagnostic methods (biomarkers, post-exertional malaise testing) detect differences in true ME/CFS incidence that self-reported symptom surveys missed?
Do specific variants of SARS-CoV-2, infection severity, or individual genetic/immunologic factors predispose certain subgroups to post-viral ME/CFS despite overall null findings?
How do the results apply to other post-viral illnesses and what mechanistic pathways might explain the similar baseline prevalence across infected and non-infected groups?